Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2009
Business Overview: Repligen is a biopharmaceutical company focused on developing novel therapeutics for central nervous system diseases and operating a bioprocessing business selling Protein A products for monoclonal antibody purification. The company also generates revenue from royalties related to the settlement of litigation with Bristol-Myers Squibb regarding the drug Orencia.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Six Months Ended Sep 30, 2009 |
|---|---|---|
| Total Revenue | $5,420,594 | $10,481,447 |
| Net (Loss) Income | $(979,703) | $(2,085,683) |
| Operating Loss | $(1,206,391) | $(2,634,114) |
| Cash and Cash Equivalents | $7,085,530 | $7,085,530 (Balance Sheet) |
| Total Marketable Securities | $53,138,004 (Amortized Cost) | $53,138,004 (Amortized Cost) |
| Total Assets | $71,643,758 | $71,643,758 |
| Total Liabilities | $4,084,628 | $4,084,628 |
| Stockholders' Equity | $67,559,130 | $67,559,130 |
| Net Cash Used in Operating Activities | N/A | $(3,433,212) |
Note: The filing does not explicitly state gross or operating margins as percentages; they are derived from the absolute figures above.
Material Changes vs. Prior Comparable Period
- Revenue: Total revenue increased 6% ($331,000) for the three months ended September 30, 2009, compared to the same period in 2008. However, for the six-month period, revenue decreased 42% ($7.9 million) compared to the prior year. This six-month decline is largely due to a one-time $6.3 million royalty payment recognized in the prior year from the Bristol-Myers Squibb settlement.
- Product Revenue: Protein A product sales decreased 8% ($242,000) in the three-month period and 39% ($3.3 million) in the six-month period, attributed to reduced demand from key customers.
- Royalty Revenue: Royalty revenue from Bristol-Myers Squibb increased to approximately $2.27 million for the three months ended September 30, 2009, compared to $1.78 million in the prior year. For the six months, it was $4.39 million versus $9.68 million in the prior year (which included the initial settlement payment).
- Operating Expenses: Total operating expenses increased 22% ($1.2 million) for the three months and 18% ($2.0 million) for the six months. Research and development (R&D) expenses rose significantly (41% for three months, 51% for six months) due to increased clinical trial activity for RG1068, RG2417, and Friedreich's Ataxia programs.
- Profitability: The company reported a net loss of $980,000 for the three months and $2.1 million for the six months ended September 30, 2009, contrasting with a net income of $142,000 and $8.4 million, respectively, in the prior year periods.
Guidance, Outlook, and Risks
- Liquidity: As of September 30, 2009, the company held approximately $60.2 million in cash, cash equivalents, and marketable securities. Management believes these funds are adequate to meet needs absent acquisitions, though future capital requirements depend on clinical trial success and potential financing needs.
- Outlook: Future revenue is expected to be limited to Protein A sales, Bristol royalties, and research grants. The company is unable to reliably estimate when therapeutic candidates will generate revenue.
- Risks: Key risks include the success of clinical trials, regulatory approvals, dependence on third-party manufacturers, and the volatility of the biotechnology marketplace. The company has a full valuation allowance against net operating losses and tax credits due to uncertainty regarding their realization.
- Unusual Items: The prior year's financial results were significantly impacted by a $5 million initial royalty payment from the Bristol-Myers Squibb settlement, which is not recurring in the current period.
Investor Verification Checklist
- Royalty Dependency: Verify the sustainability of royalty revenue from Bristol-Myers Squibb, which represented 42% of total revenue for the three months ended September 30, 2009.
- Customer Concentration: Note that the largest Protein A customer accounted for 41% of total revenue in the three-month period, and Bristol royalties represented 45% of accounts receivable.
- R&D Burn Rate: Assess the impact of the 51% increase in R&D expenses on cash reserves, driven by Phase 3 and Phase 2b clinical trials.
- Product Demand: Investigate the reasons for the 39% decline in Protein A product sales over the six-month period and the outlook for key customer demand.
- Investment Portfolio: Review the composition of the $53.1 million marketable securities portfolio, noting the company classifies them as held-to-maturity and has not recognized other-than-temporary impairment (OTTI).